Pear Therapeutics, Inc.

News Release

Pear Therapeutics to Participate in Upcoming Investor Conferences

October 8, 2020

Boston, October 8, 2020 – Pear Therapeutics, Inc. today announced management’s participation in three virtual investor conferences in October 2020:

  • Cowen 9th Annual MedTools Conference – Answers Unlocked. Corey McCann, M.D., Ph.D., President and CEO, will participate in a panel discussion, Digital Therapeutics, at this virtual conference on Thursday, October 15, 2020 at 8:30 a.m. ET.
  • 7th Solebury Trout Private Company Showcase Co-Hosted by BMO and Davis Polk. Corey McCann will present at this virtual conference on Thursday, October 15, 2020 at 11:40 a.m. ET.
  • HLTH VRTL 2020 Conference – Evercore ISI Panel Series Digging into Digital Therapeutics: A New Dimension in Treatment. Corey McCann will participate in a panel discussion, CEOs on DTx, at this virtual conference on Friday, October 16, 2020 at
    11:00 a.m. ET.

Pear Therapeutics is a privately held, prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious disease.

About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst™, for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at

Media and Investors:
Meara Murphy, Director, Corporate Communications